Jefferies Group LLC Reaffirms “Buy” Rating for MediWound Ltd. (MDWD)
Jefferies Group LLC reaffirmed their buy rating on shares of MediWound Ltd. (NASDAQ:MDWD) in a report released on Thursday morning. The brokerage currently has a $10.00 target price on the biopharmaceutical company’s stock.
A number of other analysts have also weighed in on the stock. SunTrust Banks, Inc. restated a buy rating on shares of MediWound in a research report on Monday, June 26th. Oppenheimer Holdings, Inc. restated a buy rating and issued a $10.00 target price on shares of MediWound in a research report on Monday, September 18th. Zacks Investment Research upgraded shares of MediWound from a strong sell rating to a hold rating in a research report on Wednesday, August 2nd. Finally, ValuEngine lowered shares of MediWound from a sell rating to a strong sell rating in a research report on Friday, September 22nd. Two analysts have rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus price target of $9.15.
MediWound (MDWD) traded up 7.00% on Thursday, reaching $5.35. The company’s stock had a trading volume of 94,486 shares. The firm’s market cap is $117.45 million. MediWound has a 12 month low of $4.25 and a 12 month high of $8.58. The firm’s 50 day moving average is $6.30 and its 200-day moving average is $6.53.
MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The firm had revenue of $0.69 million during the quarter, compared to the consensus estimate of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The business’s revenue was up 93.8% compared to the same quarter last year. During the same period last year, the business earned ($0.34) earnings per share. On average, equities research analysts anticipate that MediWound will post ($0.76) EPS for the current year.
Institutional investors have recently modified their holdings of the business. Wells Fargo & Company MN boosted its position in MediWound by 19.7% in the first quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares in the last quarter. Renaissance Technologies LLC boosted its position in MediWound by 1.7% in the first quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. boosted its position in MediWound by 20.3% in the second quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after buying an additional 342,165 shares in the last quarter. Finally, Wellington Management Group LLP boosted its position in MediWound by 11.0% in the first quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares in the last quarter. Hedge funds and other institutional investors own 19.55% of the company’s stock.
MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.
Receive News & Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.